Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations.

Dinunno, Corey V; Lopez, Chelsea N; Succar, Luma; Nguyen, Duc T; Graviss, Edward A; Salazar, Eric; Donahue, Kevin R

Dinunno, Corey V; Lopez, Chelsea N; Succar, Luma; Nguyen, Duc T; Graviss, Edward A; Salazar, Eric; Donahue, Kevin R.

Afiliação

Dinunno CV; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Lopez CN; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Succar L; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.
Nguyen DT; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
Graviss EA; Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Houston, Texas, USA.
Salazar E; Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Donahue KR; Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA.

Pharmacotherapy ; 42(10): 768-779, 2022 10.

Article em En | MEDLINE | ID: mdl-36054446

Assuntos

Anticoagulantes; Inibidores do Fator Xa; Administração Oral; Fator Xa; Fibrinolíticos/uso terapêutico; Hemorragia/induzido quimicamente; Humanos; Estudos Retrospectivos; Rivaroxabana

Palavras-chave

anticoagulation; direct oral anticoagulants; factor Xa inhibitors; therapeutic drug monitoring; transitions

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores do Fator Xa / Anticoagulantes Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google